Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1999-08-16
2003-03-18
Saidha, Tekchand (Department: 1652)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023500, C435S183000, C435S194000, C435S069100, C435S252300, C435S320100, C530S350000, C530S380000
Reexamination Certificate
active
06534640
ABSTRACT:
BACKGROUND OF THE INVENTION
The exposure of phosphatidylserine (PS) and other aminophospholipids (aminoPL) on the surface of activated or injured blood cells and endothelium is thought to play a key role in the initiation and regulation of blood coagulation. De novo surface exposure of aminophospholipids has also been implicated in the activation of both complement and coagulation systems after tissue injury, and in removal of injured or apoptotic cells by the reticuloendothelial system. Although migration of these phospholipids (PL) from inner-to-outer plasma membrane leaflets is known to be triggered by elevated intracellular [Ca
2+
] ([Ca
2+
]) and to be associated with vesicular blebbing of the cell surface, little is known about the cellular constituents that participate in this process.
As described in Ser. No. 08/790,186, cell surface PS has a role in coagulation, programmed cell death and clearance by the reticuloendothelial system. Ser. No. 08/790,186 also describes regulation of the transmembrane distribution of PS, the role of calcium in the collapse of phospholipid asymmetry, and the role PL translocation in Scott Syndrome.
Bassé, et al. and Stout, et al. recently reported the purification and preliminary characterization of an integral RBC membrane protein that, when reconstituted in liposomes, mediates a Ca
2+
-dependent transbilayer movement of PL mimicking plasma membrane PL reorganization evoked upon elevation of [Ca
2+
]
c
(F. Bassé, et al.,
J. Biol. Chem
. 271:17205-17210, 1996; J. G. Stout, et al.,
J. Clin. Invest
. 99:2232-2238, 1997). Evidence that a protein of similar function must also be present in platelets was recently reported by Comfurius, et al. (P. Comfurius, et al.,
Biochemistry
35:7631-7634, 1996).
Needed in the art is a method for modulating the activity of phospholipid scramblase within a cell, organ or tissue in which one wishes either to reduce the potential for thrombosis, clot formation, or cell clearance (by decreasing cellular PL scramblase expression or activity) or to promote hemostasis or cell clearance (by increasing cellular PL scramblase expression or activity).
BRIEF SUMMARY OF THE INVENTION
The present invention relates to the creation and use of antithrombotic and thrombostatic reagents that rely on the properties of a protein preparation that mediates Ca
2+
-dependent transbilayer movement of membrane phospholipids.
In one embodiment, the present invention is a preparation of a plasma membrane phospholipid scramblase (“PL scramblase”). Preferably, the protein is approximately 35-37 kD as measured on a 12.5% SDS-polyacrylamide gel under reducing conditions. In a most preferred form of this invention, the preparation is a human or a mouse PL scramblase.
In one preferred embodiment of the present invention, the PL scramblase comprises SEQ ID NO:2, representing human PL scramblase, possibly with conservative or functionally equivalent substitutions.
In the most preferred embodiment of the present invention, the PL scramblase, preferably comprising SEQ ID NO:2, has been modified by the action of mammalian cellular enzymes to covalently incorporate phosphorous at one or more Thr, Ser, or Tyr residues or a fatty acid, preferably palmitate, at a cysteine residue.
The present invention is also a preparation of a murine cell protein, wherein the protein is a plasma membrane phospholipid scramblase, preferably wherein the protein is approximately 35 kD as measured on a 12.5% SDS-polyacrylamide gel under reducing conditions.
In one preferred embodiment of the present invention, the murine PL scramblase comprises SEQ ID NO:4, possibly with conservative or functionally equivalent substitutions.
In the most preferred embodiment of the present invention, the murine PL scramblase comprising SEQ ID NO:4 has been modified by the action of mammalian cellular enzymes to covalently incorporate phosphorous one or more Thr, Ser, or Tyr residues, and a fatty acid, preferably palmitate, at a cysteine residue.
The present invention is also a DNA sequence encoding the PL scramblase. Preferably, this DNA sequence comprises SEQ ID NO:1. Most preferably, this DNA sequence comprises residues 211-1164 of SEQ ID NO:1.
The present invention is also a DNA sequence encoding the murine PL scramblase. Preferably, this DNA sequence comprises SEQ ID NO:3. Most preferably, the DNA sequence comprises residues 192-1112 of SEQ ID NO:3.
In another embodiment, the present invention is a method of preventing the surface exposure of plasma membrane phospholipids and reducing the procoagulant properties of a cell by delivering to the cell a mutant phospholipid scramblase. This scramblase is preferably mutated at a site of post-translational modification, most preferably the site is selected from the group consisting of Asp273-Asp284, Thr161 and Cys297 of human PL scramblase SEQ ID NO:2 or the corresponding conserved residues in mouse or other mammalian PL scramblase.
In one embodiment, a gene construct encoding a mutant phospholipid scramblase is delivered to the cell. In an alternative embodiment, the mutant protein itself is delivered.
The present invention is also an inhibitor of the PL scramblase activity of PL scramblase. This inhibitor may be an antisense nucleotide derived from the DNA sequence of PL scramblase. In another embodiment, the inhibitor is a peptide sequence that is a competitive inhibitor of PL scramblase activity. In another embodiment, the inhibitor is an antibody, preferably a monoclonal antibody, raised against PL scramblase.
In another embodiment, the inhibitor works by modifying or inhibiting the post-translational modifications of the PL scramblase that are disclosed below in the Examples. For example, analysis of the primary PL scramblase sequence reveals a potential site of phosphorylation by protein kinase C or other cellular kinase (Thr161), a potential site for acylation by fatty acid (Cys297), and a potential binding site for Ca
2+
ion provided by an EF-hand-like loop spanning residues Asp273-Asp284. These residues and motifs are conserved 25 in the mouse PL scramblase.
In one embodiment, the inhibitor is a compound that prevents thioacylation of the protein.
In another embodiment, a mutant phospholipid scramblase is provided in which cysteine residues, preferably Cys297 of SEQ ID NO:2 (or the equivalent residue in the conserved region of another PL scramblase), have been replaced by alanine or other non-conservative substitution.
The present invention is also a method for preventing the surface exposure of plasma membrane phosphatidylserine, phosphatidylethanolamine and cardiolipin on the surface of in vitro stored leukocytes, lymphocytes, platelets or red blood cells. This method comprises the steps of adding an inhibitor of PL scramblase activity to the stored blood cells.
The present invention is also a method for prolonging survival of transplanted organs comprising the step of adding an inhibitor of PL scramblase activity to an organ perfusate during in vitro organ storage. The present invention is also a method for prolonging the survival of transplanted cells, tissues, and organs by genetically engineering the cells to be transplanted so as to alter their expression of plasma membrane PL scramblase in order to reduce exposure of PS and other thrombogenic phospholipids at the plasma membrane surface, thereby reducing the risk of infarction due to fibrin clot formation.
The present invention is also a method for prolonging the in vivo survival of circulating blood cells (erythrocyte, platelets, lymphocyte, PMN's, and monocytes) comprising the step of preventing surface exposure of plasma membrane phosphatidylserine on the surface of the cells by exposing the blood cells to an inhibitor of PL scramblase activity.
The present invention is also a method for preventing the procoagulant activities of erythrocytes in sickle cell disease comprising the step of inhibiting erythrocyte PL scramblase in a sickle cell patient.
The present invention is also a method for treating
Sims Peter J.
Wiedmer Therese
Blood Center Research Foundation
Quarles & Brady LLP
Saidha Tekchand
LandOfFree
Methods and compositions to alter the cell surface... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions to alter the cell surface..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions to alter the cell surface... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3021744